All News
Composite MACE outcomes no different among PsA pts treated w/ biologics and DMARDs. Abs 1833 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/TxyE4Uqttq https://t.co/Eykxwmcc44
Dr. Rachel Tate uptoTate ( View Tweet)
Abst1830 #ACR21 @RheumNow d/c of TNFi in PsA/PSO: probability of d/c TNFi ⬆️ by 9.6% for each additional biologic trial. Former smoker &PsA duration correlated w/ discontinuation. most commonly reason for d/c TNFi was secondary failure (33%). infliximab had lower d/c rate https://t.co/BXd2ALX2qo
Olga Petryna DrPetryna ( View Tweet)
Deucravacitinib is a novel, oral, selective TYK2 inhibitor in PsA and selectively mediates specific inflammatory pathways (IL-23, IL-12, Type I IFN). Listen to my interview with Prof. Oliver Fitzgerald on this and his highlights https://t.co/3UJCwbHsLC
@RheumNow #ACR21 Abst#490 https://t.co/OWZDHhcQ9q
Dr. Antoni Chan synovialjoints ( View Tweet)
Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
Dr. Rachel Tate uptoTate ( View Tweet)
Methotrexate did not improve Ustekinumab efficacy in tx of PsA
⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function
#ACR21 #ACRBest @RheumNow
Abs#L12
https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Prevalent drug utilization unrelated to enthesitis in PsA. Pts on cDMARDs had higher physician globals vs those treated w/TNFi & IL-17i. In aggregate, no pattern of dz activity scores correlation w/drugs. Abs 1782 #ACR21 #RheumNow @RheumNow @doctorRBC https://t.co/x57BkBjpjo https://t.co/QmdXqOxLki
Dr. Rachel Tate uptoTate ( View Tweet)
Phase 2 trial of tildrakizumab (IL-23i) for the treatment of PsA showed lower efficacy in pts with metabolic syndrome compared to those without
#ACR21 @RheumNow
Abs#1819
https://t.co/GYHbiH9NSW https://t.co/YGcZcITjzj
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Abst1810 #acr21 @RheumNow survey of pt preferred meds for PsA points out ⬆️ interest in IL17 & PDE4 since 2018 guideline update: anti-IL17 compared to 2018 or earlier (30% vs 3.5% p< 0.001);anti-PDE4 (40% vs 11.5% p< 0.012). Meds SEs& prevention of joint damage important for pts
Olga Petryna DrPetryna ( View Tweet)
After 2018 ACR Guidelines, significant increase in IL-17i and PDE4i use in PsA pts
⭐️TNFi most common tx
⭐️28% pts not on any tx⭐️
#ACR21 @RheumNow Abs#1810
https://t.co/7Rmirfm3nK https://t.co/0Ui9pq5uyo
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
In Phase 2 trial of Tildrakizumab in active PsA efficacy tended to be lower among patients with comorbid MetS, with improvements from baseline across efficacy measures generally larger in patients without MetS vs those with MetS @RheumNow #ACR21 Abst#1819 https://t.co/ATxaFz9X2O https://t.co/2iJMNmfUzg
Dr. Antoni Chan synovialjoints ( View Tweet)
Post hoc analysis of pooled data from 19 clin trials on SEC & CV risk & systemic #inflammation in PsO, PsA, AS
📌Traditional CV parameters remained stable on all SEC treated grps
📌SEC sig. ⬇hsCRP & NLR
@RheumNow #ACR21 abs1835 https://t.co/iCaGFbXNXn
sheila RHEUMarampa ( View Tweet)
2 year study shows low rates of radiographic progression in PsA pts on guselkumab
#ACR21 @RheumNow Abs#1805
https://t.co/dobg3cEXXG https://t.co/m1P24qPAhy
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
SERENA interim analysis on interruption of secukinumab in AS and PsA
🔹>=16 wks of Rx before interruption of >= 3 mo.
🔹75-80% of pts reinitiated w/o loading phase
🔹AS: BASDAI, PGA stable
🔹PsA: SJC, TJC returned to Rx baseline
https://t.co/3G6rVW8TPv
#ACR21 Abst#1361 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Have you heard of pSpA? (Peripheral) pSpA: distinct clinical phenotype w/ intermediate features between pure PsA & pure axSpA but w/ a higher disease burden compared to both diseases, & lower use of b-DMARDs. Abs 1787 #ACR21 #ACRbest #RheumNow @RheumNow https://t.co/Wsysm7A0Y3 https://t.co/rwQ8ukBEDq
Dr. Rachel Tate uptoTate ( View Tweet)
Pregnant pts w/ PsA, but not AxSpA, at increased risk of pre-eclampsia. In RA pregnancies, pre-eclampsia risk increases w/ dz severity prior/during pregnancy. We need to discuss potential risks w/ pts and OB team. Abs 1722 #ACR21 #RheumNow @RheumNow https://t.co/yeQmNAZ1jV https://t.co/cBfeVKQHfr
Dr. Rachel Tate uptoTate ( View Tweet)
The wave of the future? Study details immune profile which discriminates PsA from PsO using phenotyping of serum immune cell subsets & machine learning. Abs 1774 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/huNTY3IdRf https://t.co/3aW64pb9UW
Dr. Rachel Tate uptoTate ( View Tweet)
Abst1783 #ACR21 #ACRBest @RheumNow Canadian study reports promising trends on hospitalizations for serious infections in PsA: 2012 – 2017 statist signif ⬇️ in discharges for sepsis, skin & soft tissue infect & UTI (p < 0.001 for all). no statistical difference in the trend of PNA https://t.co/lqtCzUFPAW
Olga Petryna DrPetryna ( View Tweet)
Upadacitinib showed similar efficacy in AS pts compared to PsA pts with axial involvement
⭐️PsA pt w/ axial involvement and AS pts with differences in baseline characteristics
#ACR21 @RheumNow
Abs#1802
https://t.co/QvyayelBYU https://t.co/50dNQm30vf
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Excellent overview on assessment of patients with #PsA by @AlexisOgdie!
Really clear and easy-to-follow slides to add structure to clinical assessment.
#ACR21 @RheumNow https://t.co/XGZrCxOukm
Mrinalini Dey DrMiniDey ( View Tweet)
Fr AQUILA study: #Uveitis status in AS or PsA pts given SEC
👁🗨3 pts w/o uveitis at BL developed new onset uveitis during study
👁🗨Most pts w/uveitis at BL - status remained unchanged or improved
👁🗨SEC did not ⬆ risk of uveitis
@RheumNow #ACR21 abs1738 https://t.co/IGUpgXBLvt
sheila RHEUMarampa ( View Tweet)
